PTC releases the latest news on ataluren, and announced the initiation of an open-label study in the European Union, Israel, Australia and Canada in addition to the US. The primary objective is to gain further information on the long-term safety and tolerability of ataluren in patients who had prior exposure to the experimental drug in a previous clinical trial. The secondary objectives of the study include specific efficacy measures. Patients will receive ataluren 3 times per day at 10, 10, 20 mg/kg (the low dose used in the previous Phase IIb trial), for approximately 48 weeks. CureDuchenne will be watching closely to see if the previous low dose Phase IIb data can be repeated with the same results.
Click here to read more.